Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.37 |
| ▸ | CNR2 | P34972 | 6/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12479482 | 0.88 | CNR1 (0.34) | CNR1CNR2ALDH1A1GRIN2BMAPK14 | |
| SCHEMBL12029926 | 0.87 | ANO1 (0.41) | HDAC1HDAC2MAPK14HDAC3 | |
| SCHEMBL247644 | 0.86 | NPC1 (0.37) | MEN1KMT2A | |
| SCHEMBL14834162 | 0.84 | SETDB1 (0.36) | CNR1CNR2MEN1ALDH1A1TSHR | |
| SCHEMBL14834082 | 0.83 | KMT2A (0.40) | CNR1CNR2MEN1ALDH1A1TSHR | |
| SCHEMBL15186069 | 0.83 | CFD (0.36) | CNR1CNR2MEN1ALDH1A1TSHR | |
| SCHEMBL12256292 | 0.83 | CHRM3 (0.32) | CNR1CNR2CHRM3HDAC1HDAC2 | |
| SCHEMBL248771 | 0.82 | KDM4E (0.31) | — | |
| SCHEMBL9980974 | 0.80 | FPR2 (0.40) | CNR1CNR2HDAC1HDAC2MEN1 | |
| SCHEMBL11888066 | 0.80 | MEN1 (0.30) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809542-B2 | Spiroheterocyclically substituted tetramic acid derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-11-07 | — | — | US | disclosed |
| US-9809542-B2 | Spiroheterocyclically substituted tetramic acid derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-11-07 | — | — | US | disclosed |
| EP-2534147-B1 | SPIROHETEROCYCLIC-SUBSTITUTED TETRAMIC ACID DERIVATIVES | BAYER IP GMBH (DE) | 2015-06-17 | — | — | EP | disclosed |
| US-20110230351-A1 | Spiroheterocyclically Substituted Tetramic Acid Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110230351-A1 | Spiroheterocyclically Substituted Tetramic Acid Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | US | disclosed |
| WO-2011098443-A1 | SPIROHETEROCYCLICAL SUBSTITUTED TETRAMIC ACID DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230351-A1 | Spiroheterocyclically Substituted Tetramic Acid Derivatives | AGXT, PTPRG, WIZ | CNR1 3516/4885CNR2 4295/4885MCHR1 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.